Ceftriaxone-induced encephalopathy in a patient with a solitary kidney.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 26 05 2022
revised: 08 07 2022
accepted: 11 07 2022
pubmed: 18 7 2022
medline: 9 9 2022
entrez: 17 7 2022
Statut: ppublish

Résumé

Ceftriaxone (CRO) is a long-acting third-generation cephalosporin antibiotic. We present a case of CRO-induced encephalopathy in an 84-year-old male patient with a solitary right kidney, admitted with bilateral pneumonia and right pyelonephritis. Intravenous CRO (2 g, every 24 hours) was started for the infection, but tonic-clonic seizures of the left face and left upper extremity appeared on the eighth day. To examine the relationship between CRO administration and the seizures, we measured CRO concentrations in the patients' plasma/serum and cerebrospinal fluid. The CRO concentration in blood at the onset of encephalopathy was estimated to have been approximately 60 μg/ml based on a simulation curve. We also calculated the pharmacokinetic parameters after CRO administration. The patient had about one-tenth of the total body clearance and one-third of the volume of distribution compared with healthy adults, and the elimination half-life was about three times longer.

Identifiants

pubmed: 35843497
pii: S1201-9712(22)00431-3
doi: 10.1016/j.ijid.2022.07.036
pii:
doi:

Substances chimiques

Ceftriaxone 75J73V1629

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

722-724

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no competing interest to declare.

Auteurs

Yuya Futagi (Y)

Department of Hospital Pharmacy, University Hospital, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan. Electronic address: futagi-yuya@staff.kanazawa-u.ac.jp.

Yuriko Ito (Y)

Department of Hospital Pharmacy, University Hospital, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.

Junya Nakade (J)

Department of Hospital Pharmacy, University Hospital, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan; Department of Infection Control and Prevention, University Hospital, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.

Arimi Fujita (A)

Department of Hospital Pharmacy, University Hospital, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan; Department of Clinical Pharmacokinetics, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.

Tsutomu Shimada (T)

Department of Hospital Pharmacy, University Hospital, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan; Department of Clinical Pharmacokinetics, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.

Misaki Yoshida (M)

Department of Rheumatology, University Hospital, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.

Yoshinori Takahashi (Y)

Department of Infection Control and Prevention, University Hospital, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan; Department of Rheumatology, University Hospital, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.

Mitsuhiro Kawano (M)

Department of Rheumatology, University Hospital, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.

Takumi Taniguchi (T)

Intensive Care Unit, University Hospital, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.

Yoshimichi Sai (Y)

Department of Hospital Pharmacy, University Hospital, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan; Department of Clinical Pharmacokinetics, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH